Stock comparison

BMYvsZTS

Bristol-Myers Squibb CovsZoetis Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.39

+16.00%

Pharmaceuticals$117.4BNYSE

ZTS

Zoetis Inc

$116.06

-2.19%

Pharmaceuticals$48.8BNYSE

60-day price, rebased to 100

BMY +6.89% · ZTS -4.81%

Round-by-round

BMY 4·ZTS 1· 1tie

EdgeBMY

Valuation upside

+2.30% vs -36.20% to DCF fair value

EdgeZTS

Balance-sheet strength

Altman Z 2.20 vs 5.39

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 6.00 (of 9)

Tie

Growth + margins

Rule-of-40 26.40 vs 26.40

EdgeBMY

60-day momentum

+6.89% vs -4.81% price return

EdgeBMY

Market-cap liquidity

$117.4B vs $48.8B

Verdict

Across6categories,BMYtakes the edge with4wins to1 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorZTS

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.